- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Reports: ESI may start 'price war' over new hepatitis C drugs
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
MORRISTOWN, N.J. — Actavis has received a preliminary approval for a generic drug for treating high blood pressure, the drug maker said Thursday.
The company said the FDA had given tentative approval to guanfacine extended-release tablets in the 1-mg, 2-mg, 3-mg and 4-mg strengths, a generic version of Shire's Intuniv. Tentative approval means a generic drug meets the basic regulatory requirements for final FDA approval, but the FDA can't approve it because the patents covering the branded version have not yet expired. Actavis said it was likely the first company to file an application for generic Intuniv with a paragraph IV certification, a legal assertion that one or more patents covering Intuniv are invalid, unenforceable or not in danger of being infringed.
Intuniv had sales of about $342 million during the 12-month period ended in March, according to IMS Health.